---
title: "EDRIC Immune Injury Accounts for One-Third Survival Penalty of Elective Nodal Irradiation in Esoph"
id: "frontiers-in-immunology-8-edric-associated-immune-injury-correlates-with-one-third-of-the-survival"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-edric-associated-immune-injury-correlates-with-one-third-of-the-survival"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1911745"
published_at: "2026-10-26T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# EDRIC Immune Injury Accounts for One-Third Survival Penalty of Elective Nodal Irradiation in Esoph
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-edric-associated-immune-injury-correlates-with-one-third-of-the-survival
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1911745)
- **Published At:** 2026-10-26T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The source article titled about **EDRIC**-associated immune injury and its relation to survival after **elective nodal irradiation** in **esophageal squamous cell carcinoma** could not be fully retrieved from the provided source body. - The available text contains journal navigation and page headers but does not include abstract, methods, cohort size, statistical outcomes, or figures. - No numerical effect sizes, hazard ratios, confidence intervals, P values, sample sizes, treatment details, or follow-up durations were present in the supplied content. - The source did not report specifics on how **EDRIC** is defined or measured in this cohort (biomarker, clinical syndrome, imaging signal, or other). - The source did not provide the protocol for **elective nodal irradiation** (dose, fractionation, fields) or comparator treatments. - The supplied material lacked description of primary and secondary endpoints, including how survival detriment was quantified or the methodology used to attribute one-third of the detriment to immune injury. - No adverse-event, translational, or immunophenotyping data were available in the provided extract. - Because the extract is incomplete, readers should consult the full Frontiers in Immunology article for validated methodology, results, and clinical context.
## Clinical Analysis & Structured Key Points
Frontiers | EDRIC-associated immune injury correlates with one-third of the survival detriment of elective nodal irradiation in esophageal squamous cell carcinoma 7.8 Gy) independently predicted worse OS (HR = 1.746; P ORIGINAL RESEARCH article Front. Immunol. , 26 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1911745 Published in Frontiers in Immunology Cancer Immunity and Immunotherapy 7 impact factor 11.3 citescore Part of a Research Topic How radiation (mis)fits into immuno-oncology: Potential implications for cancer radio-immunology Submission open 4021 views 2 articles Editor & Reviewers Edited by A A Adriana Albini Reviewed by H W Hesong Wang J C Jian Chen D L Dengxiong Li Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Table 1 Baseline characteristics of 279 ESCC patients treated with IFI or ENI before and after IPTW. View in article Table 2 Comparison of 3-, 5-, and 10-year survival outcomes across subgroups defined by field strategy and EDRIC level. View in article Table 3 Causal mediation analysis of radiotherapy field strategy on overall survival via EDRIC. View in article ORIGINAL RESEARCH article Front. Immunol. , 26 October 2026 Sec. Cancer Immunity and Immunotherapy Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1911745 EDRIC-associated immune injury correlates with one-third of the survival detriment of elective nodal irradiation in esophageal squamous cell carcinoma X R Xuejiao Ren 1 † L L Li Li 1 † X F Xiuyuan Fan 1 † S Z Shuchai Zhu 1 H Y Haitao Yang 2 W D Wenzhao Deng 1 L L Lihong Liu 1 C H Chun Han 1 * L W Lan Wang 1 * 1. Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China 2. Department of Epidemiology and Health Statistics, School of Public Health, and Hebei Province Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang, China Article metrics View details Abstract Background and purpose: The survival benefit of elective nodal irradiation (ENI) over involved-field irradiation (IFI) in ESCC remains unclear, suggesting uncharacterized systemic costs. Radiation-induced lymphopenia (RIL) is increasingly recognized as an adverse prognostic factor that may undermine antitumor immunity. We investigated whether ENI increases EDRIC, a validated dosimetric biomarker of RIL, and whether EDRIC mediates ENI’s survival disadvantage via immune injury. Methods: This retrospective cohort study analyzed 279 ESCC patients treated with definitive concurrent chemoradiotherapy (2011- 2015). EDRIC was computed using a validated model incorporating mean lung, heart, and body doses and fraction number. Inverse probability weighting balanced 14 baseline covariates. Causal mediation analysis within the counterfactual framework quantified the proportion of the total effect of radiotherapy field strategy on OS mediated by EDRIC. Results: ENI significantly elevated EDRIC compared with IFI (8.17 vs. 7.42 Gy; P = 0.01). High EDRIC (>7.8 Gy) independently predicted worse OS (HR = 1.746; P 7.3 Gy has been strongly correlated with severe lymphopenia and a substantial (50%) reduction in overall survival ( 17 ). Similarly, in esophageal adenocarcinoma, an EDRIC >4 Gy was associated with higher rates of grade 4 lymphopenia (67.3% vs. 40.8%) and inferior survival ( 18 ). We hypothesized that in ESCC, ENI, by substantially enlarging the irradiated volume, elevates EDRIC, thereby aggravating RIL and ultimately compromising survival—a relationship that may be associated with the equivocal survival benefit of ENI despite its theoretical locoregional control advantage ( 19 – 21 ). The growing integration of immune checkpoint inhibitors into CCRT regimens for esophageal cancer further underscores the need to understand how radiotherapy field design impacts host immunity. If ENI-induced elevation of EDRIC compromises survival by depleting circulating lymphocytes, then minimizing EDRIC through IFI or advanced radiotherapy techniques may serve as a tentative immunoprotective strategy requiring further multi-cohort verification. This study therefore aimed to: (1) compare EDRIC between ENI and IFI in ESCC patients treated with definitive CCRT; (2) establish the relationship between EDRIC, lymphopenia, and survival outcomes; and (3) formally quantify the extent to which EDRIC mediates the association between field strategy and overall survival using causal mediation analysis. 2 Materials and methods 2.1 Study population This retrospective cohort study was approved by the institutional review board of the Fourth Hospital of Hebei Medical University (Approval No. 2024KS209) with a waiver of informed consent. The waiver was granted because this study involved no more than minimal risk to subjects, used de-identified patient data from routine clinical practice, and it was impracticable to obtain informed consent from all eligible patients due to the retrospective nature of the data spanning a 5-year period. The study complied with the Health Insurance Portability and Accountability Act (HIPAA) and adhered to the principles of Good Clinical Practice. This study was conducted and reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. We screened patients with newly diagnosed, histologically confirmed ESCC who received definitive cisplatin-based concurrent chemoradiotherapy (CCRT) at our institution between January 2011 and December 2015. Baseline demographic and clinical characteristics, including age (recorded in years), sex, Eastern Cooperative Oncology Group performance status (0–2), body weight (measured at baseline prior to treatment initiation), tumor location, clinical TNM stage (AJCC 8th edition), and cardiopulmonary comorbidity status, were systematically extracted from electronic medical records. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Key inclusion criteria were: (1) clinical stage I–IVa or IVB (with only extra-regional lymph node metastasis) according to the American Joint Committee on Cancer (AJCC) 8th edition TNM staging system; (2) treatment with intensity-modulated radiation therapy (IMRT) to a total dose of 50.4–66 Gy using conventional fractionation (1.8–2.0 Gy per fraction); (3) Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; (4) absence of major organ dysfunction, pre-existing immune system diseases, or prior malignancies. Patients with non-squamous histology, multiple primary cancers, treatment interruptions lasting ≥1 week, or missing essential clinical or dosimetric data were excluded. Of the initial screened population (n=391), 112 patients were excluded: 25 had non-squamous histology, 15 had multiple primary cancers, 9 had treatment interruptions lasting ≥1 week, and 63 had missing dosimetric or essential clinical data. No patients were lost to follow-up within the first 5 years; after 5 years, annual follow-up was completed for 267 patients (96.0%), with 12 patients lost to follow-up due to relocation or change of contact information (attrition rate: 4.0%). Based on these criteria, 279 eligible patients were included and categorized into IFI (n=141) and ENI (n=138) groups based on radiotherapy field strategy. Sex was recorded for all patients based on medical records. The study population included 192 male (68.8%) and 87 female (31.2%) patients (see Table 1 ). Sex was included as a covariate in the propensity score model and multivariable analyses to adjust for potential sex-specific differences in treatment outcomes. Table 1 Before IPTW After IPTW Overall (n=279) IFI (n=141) % ENI (n=138) % P-value SMD Overall (n=279) IFI (n=141) % ENI (n=138) % P-value SMD Sex 0.904 0.013 0.548 -0.039 Male 192 (68.8) 98 (69.5) 94 (68.1) 190.7 (68.8) 96.5 (67.8) 94.2 (71.7) Female 87 (31.2) 43 (30.5) 44 (31.9) 82.9 (31.2) 45.8 (32.2) 37.1 (28.3) Age (years) 66 ± 8.8 67 ± 9.2 64 ± 7.9 0.002 -0.416 64 ± 9.2 65.8 ± 10.6 62.1 ± 8.5 0.953 0.008 ECOG PS 0.001 -0.133 0.913 -0.006 1 246 (88.2) 115 (81.6) 131 (94.9) 243.1 (88.8) 126.0 (88.5) 117.1 (89.1) 2 33 (11.8) 26 (18.4) 7 (5.1) 30.7 (11.2) 16.4 (11.5) 14.3 (10.9) Cardiopulmonary Comorbidity 0.002 -0.189 0.936 -0.005 Yes 139 (49.8) 57 (40.4) 82 (59.4) 140.8 (51.4) 72.8 (51.1) 68.0 (51.7) No 140 (50.2) 84 (59.6) 56 (40.6) 133 (48.6) 69.6 (48.9) 63.4 (48.3) Tumor Location 0.5 cm or a non-air-filled wall diameter >1.0 cm, as assessed by barium esophagography, endoscopy, and correlative computed tomography (CT) or positron emission tomography (PET)-CT imaging. GTV-n included lymph nodes with a short axis diameter ≥1.0 cm on CT, or nodes in specific locations (e.g., para-esophageal, tracheoesophageal groove) with a long axis ≥0.5 cm, or smaller nodes exhibiting suspicious morphology (e.g., round shape, necrosis, or high avidity on PET-CT). The Clinical Target Volume (CTV) encompassed CTV-t (GTV-t with 2–3 cm longitudinal and 0.5–0.8 cm radial margins) and CTV-n. For IFI, CTV-n was generated by expanding the GTV-n isotropically by 0.3–0.5 cm, confined strictly to the involved nodal region. For ENI, elective coverage of specific, at-risk lymphatic drainage areas was mandated based on the primary tumor location (cervical, upper, middle, or lower thoracic), encompassing relevant nodal stations as per established guidelines ( 10 ). The Planning Target Volume (PTV) was generated by uniformly expanding the respective CTV by 0.5 cm in all dimensions to account for setup uncertainties and organ motion. Organs at risk (OARs) were contoured and constrained according to standard guidelines: lung V5 ≤55–60%, V20 ≤25–30%, V30 ≤18–20%; spinal cord maximum dose <45 Gy; heart mean dose ≤30 Gy. All treatment plans were generated and delivered using IMRT techniques. Chemotherapy consisted of FP (cisplatin 25 mg/m² days 1–3, 5-fluorouracil 450–500 mg/m² days 1–5) or TP (paclitaxel 135 mg/m² day 1, cisplatin 25 mg/m² days 2–4) administered concurrently during weeks 1 and 5 of radiotherapy. 2.3 Outcome assessment and EDRIC calculation The primary survival endpoint was overall survival (OS), defined as the time from the initiation of CCRT to death from any cause. Secondary survival endpoints included progression-free survival (PFS), local-regional failure-free survival (LRFFS), and local control (LC), assessed at 3, 5, and 10 years. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, and specific radiation toxicities were graded per the Radiation Therapy Oncology Group (RTOG) criteria. Estimated Dose to Circulating Immune Cells (EDRIC) was a validated dosimetric biomarker of radiation exposure to the circulating immune cell pool, which was calculated for each patient using the previously validated formula ( 17 ): where MLD is mean lung dose, MHD is mean heart dose, MBD is mean body dose, and *n* is the number of fractions. Importantly, this EDRIC formula was originally derived and validated in non-small cell lung cancer and has not been formally calibrated for ESCC. 2.4 Statistical analysis All statistical analyses were performed using R software (version 4.1.3; R Foundation for Statistical Computing, Vienna, Austria; RRID: SCR_001905). This was a retrospective cohort study, and thus patients were not randomly assigned to the IFI or ENI groups; treatment decisions were made based on institutional protocols and physician discretion based on tumor location and nodal involvement. To mitigate selection bias and confounding by indication, we employed inverse probability of treatment weighting (IPTW). Propensity scores were estimated using a logistic regression model that included 14 pre-specified baseline covariates. Covariate balance between the IFI and ENI groups before and after IPTW application was assessed using standardized mean differences (SMD), with an SMD <0.1 indicating adequate balance. Outcome assessors and statisticians were blinded to the radiotherapy field assignment during the analysis phase. Clinical data were abstracted from electronic medical records by trained research assistants who were not involved in treatment planning and were blinded to the study hypothesis. The primary endpoint (overall survival) was objectively defined as death from any cause, which is not subject to assessment bias. Survival analyses were performed using the Kaplan-Meier method, and between-group differences were compared using the log-rank test. Univariable and multivariable Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of EDRIC, field strategy, and other clinical factors with survival endpoints. The proportional hazards assumption for Cox regression models was tested using Schoenfeld residuals (global test P = 0.31), with no significant violation detected. Notably, the IPTW model separately included cT, cN and cM as three independent covariates to finely balance baseline features (14 total covariates). For multivariable Cox regression, we merged the three separate stage variables into one composite TNM stage, additionally adjusted for three post-treatment toxic adverse events, and incorporated two core study predictors (radiation field strategy, EDRIC grouping), resulting in a total of 17 adjusting factors. Causal mediation analysis was conducted within the counterfactual framework using the cmest function from the CMAverse package in R (version 0.1.0). This analysis decomposes the total effect (TE) of the radiotherapy field strategy (ENI vs. IFI) on OS into a natural direct effect (NDE; effect not through EDRIC) and a natural indirect effect (NIE; effect mediated through EDRIC). The models were adjusted for the same baseline covariates used in IPTW and included an exposure-mediator interaction term. Effect estimates (expressed as risk ratios, RR) were derived via the imputation approach, and 95% CIs were computed based on 20, 000 non-parametric bootstrap samples. The proportion mediated (pm) was calculated as ln(NIE)/ln(TE). Note that this log-ratio-based proportion-mediated estimator for the risk-ratio scale should be interpreted with caution; it is not identical to the risk difference-based proportion mediated. All statistical tests were two-sided, and P values <0.05 were considered statistically significant. Exact p-values are reported in the results section; for p<0.001, we report as p<0.001. This was a retrospective cohort study using a consecutive sample of eligible patients treated between 2011 and 2015; therefore, sample size was d
## Related Clinical Research

- [Cadonilimab-associated multi-organ damage: case report overview and missing details](https://medichelpline.com/clinical-feed/frontiers-in-immunology-14-case-report-severe-multi-organ-damage-induced-by-cadonilimab-mechanism.md)
- [Neoadjuvant serplulimab plus chemotherapy achieves high MPR in locally advanced squamous NSCLC](https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-neoadjuvant-serplulimab-combined-with-chemotherapy-in-locally-advanced-driver.md)
- [Pollen size shifts after whole genome duplication in autotetraploids](https://medichelpline.com/clinical-feed/biorxiv-17-biased-evolution-of-pollen-size-after-whole-genome-duplication.md)
- [Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings](https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced.md)
- [TX5 photosensitizer targets mitochondrial DNA G-quadruplexes to bypass cisplatin resistance in lun](https://medichelpline.com/clinical-feed/pubmed-42933202.md) (DOI: 10.1016/j.bioorg.2026.110694)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.